2[12]Lazarus JH, Obuobie K. Thyroid disorder-an update. Postgrad Med J, 2000, 76(899): 529 被引量：1
3[13]Quadro L, Panariello L, Salvatore D, et al. Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab, 1994, 79(2): 590 被引量：1
4[14]Bongarzone I, Pierotti MA, Monzini N,et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene, 1989, 4(12): 1457 被引量：1
5[15]Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med, 2002, 43(9): 1188 被引量：1
6[1]Mishra A, Agarwal A, Agarwal G, et al. Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg, 2001, 25(3): 307 被引量：1
7[2]Gimm O, Brauckhoff M, Thanh PN, et al. An update of thyroid surgery. Eur J Nucl Med, 2002, 29(supple 2): s447 被引量：1
8[3]Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994, 97(5): 418 被引量：1
9[4]Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab, 1992, 75(3): 714 被引量：1
10[5]Udelsman RA. Differentiated thyroid cancer: less than total thyroidectomy. Ann Surg Oncol, 2000, 7(5): 382 被引量：1
